# cfDNA & evProtein

> [**PDFs**](https://cloud.tsinghua.edu.cn/d/07d2b19d6b284ebea5ea/?p=%2F2.%20Precision%20Medicine\&mode=list)****

## 1. ctDNA/cfDNA

* **cfDNA - Nucleosome footprint & short cfDNA**
  * **✨2021 **_**Science Trans. Med.**_ - Analysis of recurrently protected genomic regions in cell-free DNA found in urine
  * \[nuc. footprint + motif + frag. + 5HmC] **2021 **_**Cell Res.**_** ** Genome-scale profiling of circulating cell-free DNA signatures for early detection of hepatocellular carcinoma in cirrhotic patients
  * **✨2016 **_**Cell**_** ** - Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin
  * **2021** _**Genome Res.** _ - Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA
* **cfDNA - Frag. +**&#x20;
  * _**2021 Hepatology**_ - Ultra‐Sensitive and Affordable Assay for Early Detection of Primary Liver Cancer Using Plasma cfDNA Fragmentomics
  * **✨**\[Frag. size + CNV + mtDNA%] ** **_**2019 Nature**_ - Genome-wide cell-free DNA fragmentation in patients with cancer&#x20;
  * _**2018 Science Trans. Med.**_ - Enhanced detection of circulating tumor DNA by fragment size analysis
* **cfDNA - mbDNA** (Microbiome of cfDNA)
  * **✨ **_**2020 Nature**_ - Microbiome analyses of blood and tissues suggest cancer diagnostic approach&#x20;
* **ctDNA - Mutations+**&#x20;
  * **2020** _**Nature Med**_. - Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring
  * **captured ctDNA SNV+CNV: **_**2020 Nature**_ - Integrating genomic features for noninvasive early lung cancer detection
  * _**2019 Nature Medicine**_ - Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study
  * **Papadopoulos N Lab**
    * _**2020 Science -**_ **ctDNA+PET-CT -** Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention
    * **✨ **_**2018 Science -**_ **ctDNA+Protein(CancerSEEK)** - Detection and localization of surgically resectable cancers with a multi-analyte blood test



## **2. cfDNA Methylation**

* **TAPS**
  * **✨**\[cfTAPS] **2021 **_**Science Advances**_ - Cell-free DNA TAPS provides multimodal information for early cancer detection
  * **✨**\[TAPS] **2019 **_**Nature Biotech.** _ - Bisulfite-free direct detection of 5-methylcytosine and 5-hydroxymethylcytosine at base resolution
* **MeDIP**
  * **2020** _**Nat Medicine**_ - Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes
  * **✨**\[cfMeDIP] **2019 **_**Nature Protocol** _ - Preparation of cfMeDIP-seq libraries for methylome
  * **✨**\[cfMeDIP] _**2018 Nature**_ - Sensitive tumour detection and classification using plasma cell-free DNA methylomes
* **BS**&#x20;
  * **2021** _**Nature Biomedical Engineering**_ - Ultrasensitive detection of circulating tumour DNA via deep methylation sequencing aided by machine learning
  * **✨** \[Targeted BS] _**2021 Annals of Oncology**_ - **Grail and CCGA Consortium** - Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set
  * **✨** \[Targeted BS] _**2020 Annals of Oncology**_ - **Grail and CCGA Consortium -** Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
  * \[chips] _**2018 Nature**_ - DNA methylation-based classification of central nervous system tumours
  * \[WGBS] _**2017 Nature Genetics**_ -  Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA
  * \[WGBS] **2013 **_**PNAS**_ - Noninvasive detection of cancer-associated genome- wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing
* **5Hmc**
  * _**2019 Gut**_ - Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma
  * _**2019 Blood Adv**_ - Prognostic implications of 5-hydroxymethylcytosines from circulating cell-free DNA in diffuse large B-cell lymphoma
  * _**2017 Cell Res**_ - 5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers

### More reading on cfDNAmet-seq

* _**2020 Sci Adv**_ - Reliable tumor detection by whole-genome methylation sequencing of cell-free DNA in cerebrospinal fluid of pediatric medulloblastoma.&#x20;
* _**2019 Clin Chem**_ - Detection of Colorectal Cancer in Circulating Cell-Free DNA by Methylated CpG Tandem Amplification and Sequencing
* _**2017 Genomic Medicine**_ - Empirical comparison of reduced representation bisulfite sequencing and Infinium BeadChip reproducibility and coverage of DNA methylation in humans.
* _**2015 Cell Res**_ - Genome-scale detection of hypermethylated CpG islands in circulating cell-free DNA of hepatocellular carcinoma patients&#x20;
* _**2014 Clin Epigenetics**_ - Genome-wide methylation profiling of the different stages of hepatitis B virus-related hepatocellular carcinoma development in plasma cell-free DNA reveals potential biomarkers for early detection and high-risk monitoring of hepatocellular carcinoma.

### Validation of DNAmet

* \[mqMSP] **2021 PNAS** - Efficient detection and post-surgical monitoring of colon cancer with a multi-marker DNA methylation liquid biopsy
* \[qMSP]**2019  Clin Epigenetics** - Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood
* \[MSRE] **2016 Clin Epigenetics**  - Detection and monitoring of hypermethylated RASSF1A in serum from patients with metastatic breast cancer
* \[qMSP] **2019 Theranostics** - Genome-wide discovery and validation of diagnostic DNA methylation-based biomarkers for hepatocellular cancer detection in circulating cell free DNA



## 3. EV Proteomics

* **✨** \[MS-EVP] _**2020 Cell**_ - Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers
* \[APPA] _**2020 Sci Adv** -_ Proteomic analysis of circulating extracellular vesicles identifies potential markers of breast cancer progression, recurrence, and response

